4//SEC Filing
Harmon J Frank 4
Accession 0001181431-08-053262
CIK 0001141399other
Filed
Sep 14, 8:00 PM ET
Accepted
Sep 15, 7:29 PM ET
Size
12.2 KB
Accession
0001181431-08-053262
Insider Transaction Report
Form 4
Harmon J Frank
Exec. VP and COO
Transactions
- Disposition to Issuer
Common Stock
2008-09-10−15,812→ 0 total - Disposition to Issuer
Nonqualified Stock Option (Right to Purchase)
2008-09-10$15.17/sh−51,778$785,472→ 0 totalExercise: $7.83Exp: 2016-05-22→ Common Stock (51,778 underlying) - Disposition to Issuer
Common Stock
2008-09-10−10,018→ 0 total - Disposition to Issuer
Incentive Stock Option
2008-09-10$15.17/sh−26,353$399,775→ 0 totalExercise: $7.83Exp: 2016-05-22→ Common Stock (26,353 underlying)
Footnotes (4)
- [F1]Disposed of pursuant to the Agreement and Plan of Merger, dated as of July 6, 2008, among Fresenius SE, Fresenenius Kabi Pharmaceuticals Holding, Inc. (formerly Frensenius Kabi Pharmaceuticals Holding LLC), Fresenius Kabi Pharmaceuticals, LLC (?Merger Sub?) and APP Pharmaceuticals, Inc. (?APP?), whereby Merger Sub merged into APP with APP continuing as the surviving company and an indirect wholly owned subsidiary of Fresenius SE (the ?Merger?), in exchange for (x) an amount in cash equal to $23.00 plus (y) a contingent value right issued by Holdco.
- [F2]Represents restricted stock units issued to the Reporting Person. Each restricted stock unit, which represents a contingent right to receive one share of common stock, was cancelled in the Merger in exchange for a cash payment of $363,676, the value of the total number of restricted stock units multiplied by $23.00.
- [F3]Pursuant to the Merger, this option, which was granted on May 22, 2006 and 25% of which vests per year for four years from the anniversary of the grant date, was cancelled in exchange for a cash payment of $206,344, which represents the excess of $23.00 per share over the exercise price per share of this option.
- [F4]Pursuant to the Merger, this option, which was granted on May 22, 2006 and 25% of which vests per year for four years from the anniversary of the grant date, was cancelled in exchange for a cash payment of $405,422, which represents the excess of $23.00 per share over the exercise price per share of this option.
Documents
Issuer
APP Pharmaceuticals, Inc.
CIK 0001141399
Entity typeother
Related Parties
1- filerCIK 0001364845
Filing Metadata
- Form type
- 4
- Filed
- Sep 14, 8:00 PM ET
- Accepted
- Sep 15, 7:29 PM ET
- Size
- 12.2 KB